Digistain ® - Leading digital transformation in cancer diagnostics - radically faster gold standard risk scoring analytics at a dramatically lower cost A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), DIGISTAIN® is a patented risk profiling test for hormone receptor-positive breast cancer patients. Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required. The MHRA approved DIGISTAIN technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain.
External link for Digistain®
Unit 101, Interchange Business Park,
Howard Way,
Newport Pagnell, , MK16 9PY, GB
Digistain® reposted this
🚨 LATEST FEMTECH EPISODE 🚨 In this episode of The FemTech Series, you can hear Olivia Friett, editor of Medical Plastics News talk to Hemmel Amrania PhD Breast Cancer Diagnostics CEO of Digistain®, a company that has won multiple awards for its transformative breast cancer biomarker analytics. You can hear the full episode here: https://lnkd.in/etZMxeyZ Or wherever you listen to podcasts! #femtech #womenshealth #cancer #diagnostics #breastcancer
Excellent summary by Nature https://lnkd.in/e9M4gymn of our technology and the fundamental challenges associated with traditional #breastcancer diagnostics that Digistain® was invented to solve. Thank you to the Nature team and to Claire Ainsworth for the comprehensive write-up. Hemmel Amrania PhD Breast Cancer Diagnostics “What I noticed, was there was an opportunity to make a bigger impact, both with the patients and with the clinical pathway, if we were to deliver a test result far more quickly but also far more accessibly.” By transforming the analysis of key biomarkers from a long costly manual wet-lab process to a rapid affordable AI-enabled solution Digistain promises to eliminate global breast cancer care inequalities. Chris Phillips Imperial College London #innovation #pathology #oncology
We are thrilled to share the announcement today that Digistain® are 1 of 4 FINALISTS for the 2024 Nature Spin-off Prize https://lnkd.in/eKCxDeEr. Over 150 innovative technologies were diligently evaluated by a world-class panel of leading scientists so we are very proud that our novel approach to #breastcancer #diagnostics has been recognised by this prestigious award panel. Traditional methods of identifying #biomarkers to predict breast cancer recurrence risk are slow and expensive. Established biomarkers are very difficult to measure in a lab setting meaning an accurate risk recurrence test is unavailable to 95% of breast cancer patients around the world meaning chemotherapy is their first line of defence. By transforming the analysis of key biomarkers from a long costly manual wet-lab process to a rapid affordable AI-enabled solution Digistain promises to eliminate global breast cancer care inequalities.
It's an honour to be recognised by Nature as a shortlisted company for The Spinoff Prize 2024 https://lnkd.in/eKCxDeEr. Over 150 innovative technologies were diligently evaluated by a world-class panel of leading scientists so we are delighted that our novel approach to #breastcancer #diagnostics has been nominated for the finals. Traditional methods of identifying biomarkers to predict breast cancer recurrence risk are slow and expensive. Established #biomarkers are very difficult to measure in a lab setting meaning an accurate risk recurrence test is unavailable to 95% of breast cancer patients around the world meaning chemotherapy is their first line of defence. By transforming the analysis of key biomarkers from a long costly manual wet-lab process to a rapid affordable AI-enabled solution Digistain promises to eliminate global breast cancer care inequalities.
After a very rigorous evaluation process we have been shortlisted by Springer Nature Group for The Spinoff Prize 2024 which recognises innovative science focused companies for originality and commercial potential. https://lnkd.in/eKCxDeEr
In Munich as part of the EIT Health 2024 Catapult Award finalists. Thank you to EIT, the judges and sponsors for the recognition as a leading European innovator in #healthcare.
Wonderful to be one of the 9 finalists and only 1 of 2 UK companies nominated. Good luck to all next week in the grand final. Hemmel Amrania PhD Breast Cancer Diagnostics
📣 Exciting News! Two UK start-ups, Digistain® and Celex Oncology Innovations Ltd, have secured spots in the EIT Health Catapult Finals which will be held at the health.tech conference in Munich on 5th June. Nine European start-ups will compete in the finals. These finalists represent the most promising European start-ups in the life sciences and healthtech sectors. 👉 Read more: https://lnkd.in/dx7MEcpP Join us at the Health.Tech 2024 conference to see the finalists compete among Europe's most promising health innovators. What are your waiting for? Secure your spot: www.health.tech
Great to be partnered with CORE Diagnostics bringing our groundbreaking #breastcancer diagnostics technology to patients in #india https://lnkd.in/ew_u54cS
Thank you health.tech conference - the brilliant Hemmel Amrania PhD Breast Cancer Diagnostics explaining how we are providing patients with dramatically faster #breastcancer risk recurrence diagnostics
"As medical research scientists, ‘hope’ as a strategy for cancer care was not an option. We wanted to turn the hope that clinicians and their patients would get an accurate predictive test in good time, and at an affordable price, into a reality." Find out more about Digistain®'s story below. Enjoy the💡 "Pitch of the Day", your daily dose of healthcare innovations, that we will share on a daily basis here between May, 1st - 31st. (27) Only 8 days left - May, 27th 2024 Digistain® Hemmel Amrania Digistain® is pioneering the growing use of spectrometry in cancer diagnostics. Through biopsy imaging, they analyze wavelengths that are known to be absorbed by nucleic acids and cell proteins. This imaging approach enables Digistain® to measure chemical concentrations associated with tumour malignancy, precisely determine the characteristics of cancer cells and quantify validated pathology markers correlated to tumour proliferation. Join now 👉 https://lnkd.in/ePSTmH-c
We've had a great 4 days at #ADGHW Abu Dhabi Global Healthcare Week showcasing how our technology phenotypes breast cancer and generates a deeper understanding of disease characteristics, progression and susceptibility. Thank you to the excellent teams at @healthcare-UK-dept @UKinUAE and Department for Business and Trade for organising such a valuable and engaging programme.